Media headlines about Arena Pharmaceuticals (NASDAQ:ARNA) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Arena Pharmaceuticals earned a coverage optimism score of 0.11 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.6384769218093 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:
A number of brokerages have recently commented on ARNA. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $37.00 price objective on shares of Arena Pharmaceuticals in a research report on Monday, September 25th. BidaskClub raised Arena Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 2nd. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $36.00.
Shares of Arena Pharmaceuticals (ARNA) opened at $30.75 on Thursday. Arena Pharmaceuticals has a 1 year low of $11.30 and a 1 year high of $31.75. The company has a debt-to-equity ratio of 0.27, a current ratio of 4.42 and a quick ratio of 4.32.
Arena Pharmaceuticals (NASDAQ:ARNA) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.66) by $0.01. Arena Pharmaceuticals had a negative return on equity of 34.12% and a negative net margin of 36.78%. The firm had revenue of $7.95 million during the quarter, compared to the consensus estimate of $5.48 million. During the same quarter in the previous year, the business earned ($0.05) earnings per share. The firm’s quarterly revenue was down 58.6% compared to the same quarter last year. equities analysts predict that Arena Pharmaceuticals will post -3 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Arena Pharmaceuticals (ARNA) Receiving Somewhat Positive Press Coverage, Study Shows” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2017/12/07/arena-pharmaceuticals-arna-receiving-somewhat-positive-press-coverage-study-shows.html.
About Arena Pharmaceuticals
Arena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn’s disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH).
Receive News & Ratings for Arena Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arena Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.